Contract Manufacturing in the Development of New Gene Therapies for Rare Disorders

Time: 1:30 pm
day: Day 2 Track A afternoon


  • A choice of approaches is possible depending on the business model adopted
  • Design early for manufacture and consider the operability of the process at the proof of concept stage
  • The European CDMO system is healthy and there are things that public sector organisations can do to make it better still